Skip to main content
Equibles
PBYI logo

PBYI · Puma Biotechnology, Inc. · Metrics

Track PBYI — free

Use PBYI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$9.39 -0.16 (-1.68%)
Russell 2000 member Rebalance outlook locked
Market Cap
$492.97M
Shares
51.62M

PBYI metrics

84 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.55
Market cap
$492.97M

Price action

20 metrics
Price change (1W)
+5.4%
Price change (30D)
+9.9%
Price change (3M)
+35.8%
Price change (6M)
+57.9%
Price change (YTD)
+60.5%
Price change (1Y)
+86.9%
Trailing year
Price change (5Y)
+29.2%
52-week high
$9.69
52-week low
$4.34
Change from 52-week high
-1.4%
Change from 52-week low
+120.0%
Annualized volatility
60.0%
Annualized volatility (3M)
44.2%
Beta
0.6
RSI (14D)
61.9
Price vs SMA 50
+12.0%
Price vs SMA 200
+35.2%
Avg volume (3M)
326,825
Relative volume
0.6
Average dollar volume
$2.72M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
51.62M

Valuation

12 metrics
P / E (TTM)
18.4
Trailing earnings · reciprocal yield 5.4%
PEG ratio
0.6
EV / revenue
1.7×
reciprocal yield 57.9%
EV / EBITDA
9.8×
reciprocal yield 10.3%
EV / EBIT
13.1×
reciprocal yield 7.6%
P / sales
2.1×
reciprocal yield 46.9%
P / book
3.6
reciprocal yield 28.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
12.0
reciprocal yield 8.3%
Earnings yield
5.4%

Historical valuation

8 metrics
P / E historical average (3Y)
12.3×
reciprocal yield 8.1%
P / E historical average (5Y)
13.2×
reciprocal yield 7.6%
EV / revenue historical average (3Y)
0.9×
reciprocal yield 114.0%
EV / revenue historical average (5Y)
0.8×
reciprocal yield 120.8%
EV / EBIT historical average (3Y)
6.6×
reciprocal yield 15.2%
EV / EBIT historical average (5Y)
11.9×
reciprocal yield 8.4%
EV / EBITDA historical average (3Y)
4.6×
reciprocal yield 21.7%
EV / EBITDA historical average (5Y)
5.1×
reciprocal yield 19.7%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
74.8%
Operating margin
13.2%
Trailing 12 months
Net margin
11.6%
Gross profit (TTM)
—
Operating profit (TTM)
$30.44M
Net income (TTM)
$26.72M
Trailing 12 months
Diluted EPS (TTM)
$0.52
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
+7.8%
Year over year
Net income growth YoY
+39.9%
Revenue (TTM)
$231.24M
Trailing 12 months
EPS growth YoY
+33.3%
Shares change YoY
+4.9%
Year over year · more shares
Revenue CAGR (3Y)
+0.0%
Revenue CAGR (5Y)
+0.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
+124.8%

Quality

14 metrics
Return on equity
19.3%
Return on assets
13.9%
Debt / equity
0.0
Current ratio
2.9
EBITDA (TTM)
$40.91M
Free cash flow (TTM)
—
Quick ratio
2.6
Interest coverage
8.6
Net debt / EBITDA
-2.3
Return on invested capital
—
Trailing 12 months
Net cash
$93.90M
Latest balance sheet
Cash & equivalents
$36.54M
Total assets
$192.74M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$41.15M
Capital expenditures (TTM)
$10,000
R&D (TTM)
$71.44M
SG&A (TTM)
$71.17M
Stock compensation (TTM)
$7.14M
R&D / revenue
30.9%
Stock compensation / revenue
3.1%

Ownership (13F)

3 metrics
13F filers
162
13F filer change QoQ
+4
Institutional ownership
75.1%

Short interest

3 metrics
Short interest
8.1%
Latest settlement · 11.4 days to cover
Days to cover
11.4d
Short-squeeze score
69 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$1.08M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1401667 CUSIP 74587V107 13F (30d) 101 filings 101 filers Visit website Investor relations